{"analyses":[{"ciLowerLimit":".74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","groupDescription":"Estimated hazard of first progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":".89"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.5","upperLimit":"15.8","value":"14.7"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"15.2","value":"14.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"346"}],"units":"Participants"}],"description":"First progression or death for weekly paclitaxel treatment relative to standard 3 week paclitaxel. Progression is defined using response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV","id":"OG000","title":"Arm I (Adjuvant Chemotherapy Suboptimally Debulked)"},{"description":"Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG001","title":"Arm II (Neoadjuvant Chemotherapy)"}],"paramType":"MEDIAN","populationDescription":"Whole sample","reportingStatus":"POSTED","timeFrame":"The timeframe is from enrollment onto the study up to 3 years following enrollment.","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"months"}